B
Bull
Bull · 25%PTCT
$146.32
Precio del escenario
$70.090
-1.682 (-2.40%)Al cierre
Loading chart…
- High
- 71.490
- Open
- 71.080
- VWAP
- 70.40
- Vol
- 692.67K
- Mkt Cap
- 2.66B
- Low
- 69.610
- Amount
- 48.76M
- EV/EBITDA, TTM
- 8.85
PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).
AI analysis of PTC Therapeutics Inc (PTCT)
buyPTC Therapeutics Inc is a good buy right now due to its recent strong earnings report, which showed a Q2 GAAP EPS of $0.92, exceeding expectations by $0.71, and a revenue of $360.5 million, marking a 101.5% year-over-year increase. Additionally, the stock has a forward P/E of 39.68, indicating growth potential, while analysts have set price targets significantly above the current price of $70.09, with the highest target at $109. The main risk is the current RSI of 37.045, suggesting that the stock is oversold, but this can also present a buying opportunity.
Analyst Ratings (8)
+11.54% upside
Hold
2 Buy
5 Hold
1 Sell
Current: 70.09
Mínimo
54.00
Promedio
78.18
Máximo
118.00
Wells Fargo
Overweight
$109
2026-08-13
Wells Fargo
2026-08-13
Precio objetivo
$109
Overweight
BofA
Buy
$96
2026-07-31
BofA
2026-07-31
Precio objetivo
$96
Buy
Morgan Stanley
Overweight
$104
2026-07-31
Morgan Stanley
2026-07-31
Precio objetivo
$104
Overweight
Wells Fargo
Overweight
$106
2026-07-31
Wells Fargo
2026-07-31
Precio objetivo
$106
Overweight
Wells Fargo
Overweight
$93
2026-07-20
Wells Fargo
2026-07-20
Precio objetivo
$93
Overweight
Métricas de valoración
The current forward P/E ratio for PTC Therapeutics Inc (PTCT) is 39.68, compared to its 5-year average forward P/E of -4.28.
Alphio AI Price Scenarios for PTCT
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding PTCT
Cronología de eventos
Noticias
8.508-13NASDAQ.COMPTC Therapeutics Acquires ST-920 Gene Therapy for Fabry Disease
9.507-30seekingalphaPTC Therapeutics Q2 Earnings Exceed Expectations
5.007-23PRnewswireHamilton Lane Appoints New Independent Director
9.507-16PRnewswirePTC Therapeutics to Host Q2 2026 Earnings Call
5.007-14FoolPTC Therapeutics Executive Stock Transaction Overview
PTCT FAQ — answered by Alphio AI
PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
PTC Therapeutics Inc is a good buy right now due to its recent strong earnings report, which showed a Q2 GAAP EPS of $0.92, exceeding expectations by $0.71, and a revenue of $360.5 million, marking a 101.5% year-over-year increase. Additionally, the stock has a forward P/E of 39.68, indicating growth potential, while analysts have set price targets significantly above the current price of $70.09, with the highest target at $109. The main risk is the current RSI of 37.045, suggesting that the stock is oversold, but this can also present a buying opportunity.
8 analysts cover PTCT: 2 rate it Buy, 5 Hold and 1 Sell. The average price target is 78.18.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.